103 articles - From Friday Nov 21 2025 to Friday Nov 28 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
| Impact of guideline-concordant post-polypectomy colonoscopy surveillance on colorectal cancer incidence and mortality.
Follow-up concordant with post-polypectomy surveillance guidelines is associated with reduced risk of incident CRC, but impact on risk of fatal CRC requires further study. Many post-polypectomy CRC events occur early in the surveillance window, underscoring importance of baseline colonoscopy quality in influencing post-polypectomy CRC risk. |
| Gastroenterology |
| AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.
This guideline provides a comprehensive, patient-centered, evidence-based approach to the pharmacologic management of patients with moderate-to-severely active CD. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease.
Double-dose HBV vaccination significantly improved AIR and EIR over standard-dose. These findings support a double-dose strategy to optimize seroconversion in patients with IBD, especially those receiving immunosuppressive therapy. |
| Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis.
LYS006 20 mg bid monotherapy and LYS006 20 mg bid+tropifexor 200 μg qd therapy were well tolerated with the exception of a high frequency of pruritus in the combination arm, consistent with the now known pharmacologic effect of farnesoid X receptor agonists. The greater reductions in ALT and liver fat in the combination arm versus monotherapy arm were similar to those observed with tropifexor as monotherapy in a previously reported phase 2 clinical trial, and clear additional benefit was not observed in combination treatment with LYS006. This study design allowed for rapid screening of potentially high efficacy drug combinations in MASH. |
| Am J Gastroenterol |
| Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers.
We also examine its impact on quality of life, evaluate current assessment tools, and highlight therapeutic approaches and gaps in HCP-patient communication. Greater awareness and systematic evaluation of BU as a multidimensional symptom of CD are critical for optimizing care and aligning clinical management with patient priorities. |
| Empirical Antifungal Therapy Improves Survival in patients with Acute-on-Chronic Liver Failure with Suspected Invasive Fungal Infections: A Pragmatic Randomised Trial.
Early empirical antifungal therapy within a structured stewardship framework improves survival in patients with ACLF and IFIs. Timely recognition, rapid diagnostics, and individualized antifungal strategies are essential to bridge these high-risk patients towards recovery or definitive therapies. |
| Mildly Elevated Lipase and Subsequent Risk of Acute Pancreatitis and Pancreatic Cancer.
MEL was associated with increased long-term AP risk. |
| Performance of an Artificial Intelligence-Powered Smartphone Application in Identifying Gluten-Free Foods for Individuals with Celiac Disease.
With rigorous evaluation, AI-powered tools may support dietary adherence for patients with CD. |
| TRENDS IN THE ULCERATIVE COLITIS TO CROHN'S DISEASE INCIDENCE RATIO ARE DISTINCT BETWEEN EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE.
Decreasing UC CD incidence ratios signal a rising burden of CD, underscoring the need to anticipate greater healthcare demand, including higher treatment costs and higher prevalence of complications. |
| Women and Younger Adults with Inflammatory Bowel Disease are at Greater Risk for Financial Toxicity from IBD.
Financial toxicity was prevalent among patients with IBD, particularly among younger adults, those with lower income and education and women. Enquiring about financial toxicity should be incorporated into IBD clinical practice. |
| Clin Gastroenterol Hepatol |
| Chronic kidney disease does not influence response to terlipressin in hepatorenal syndrome - acute kidney injury.
CKD does not adversely affect treatment response to terlipressin or survival in patients with HRS-AKI. |
| Circulating Metabolite Signatures Linking Physical Activity to Inflammatory Bowel Disease Risk and Interactions with Genetic Susceptibility.
Our findings indicate a potential role of MVPA in the prevention of IBD, particularly in individuals with a heightened genetic predisposition, and point to possible biological pathways through which physical activity may influence the incidence of IBD. |
| Cluster Analysis of Fecal Incontinence Symptoms: Associations With Anorectal Physiology and Quality of Life.
FI characteristics were weakly but significantly associated with BMs and anorectal functions. Diary-captured stool and FI patterns identified 4 phenotypes associated with FI-based QoL and anorectal function. This stratification will likely facilitate the management of FI. |
| Endoscopic response to subcutaneous infliximab by disease location: A post hoc analysis of the LIBERTY-CD study.
Although ileal disease is often more treatment-resistant, IFX SC maintenance therapy was effective versus PBO regardless of disease location, demonstrating consistent efficacy across segments including the terminal ileum. |
| Esophageal Function Testing Identifies Barrett's Esophagus Patients With Pathological Acid Exposure at Risk for Neoplasia.
Nearly one-third of asymptomatic patients with BE exhibit pathological reflux on pH-monitoring despite PPI treatment. Nonetheless, normal AET is found in another one-third of patients on standard-dose PPI. Pathological reflux is associated with a 9-fold increased risk of neoplasia. |
| High prevalence of disorders of irritable bowel syndrome and functional dyspepsia in night shift workers: a cross-sectional study in Australia and the UK.
Night shift workers have a substantially higher prevalence of IBS and FD compared to reported general population rates, with significant impacts on IBS-specific quality of life and mental health. These findings highlight the need for targeted interventions to support gastrointestinal and mental health in this vulnerable working population. |
| Impact of Model for End-stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates.
Although MELD 3.0 reclassifies a substantial proportion of patients with MASH-particularly women-it does not appear to increase transplant access despite higher predicted mortality risk. These findings highlight residual gaps in how MELD 3.0 captures clinical risk in MASH cirrhosis and underscore the need for prospective data following its implementation. |
| Optimizing evaluation of gastroesophageal reflux with atypical symptoms: Cost-effectiveness and cost-minimalization analysis.
Phenotyping the approach to the dominant symptom may optimize evaluating patients with atypical GERD symptoms. These conclusions are consistent with the Lyon 2.0 and San Diego consensus recommendations of treatment avenues distinct from GERD management. |
| Prevalence and associated factors of fecal incontinence: a global population-based study. Fecal incontinence in the global population.
FI is common across the globe, but with regional differences. Strong associations with abdominal and rectal pain, as well as diarrhea- and constipation-specific symptoms suggest a role of both altered stool consistency and visceral hypersensitivity in FI pathophysiology. |
| Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
These recommendations may help to standardize study design and conduct and foster clinical development of much needed therapies for this debilitating manifestation of CD. |
| Risk of variceal hemorrhage in patients with cirrhosis taking calcium-channel blockers.
CCBs were not associated with an increased risk of VH in patients with cirrhosis compared with ACEIs/ARBs. These findings suggest that CCBs are a safe treatment option for patients with cirrhosis and hypertension, providing valuable guidance on medication selection in this vulnerable population. |
| Sugar Rationing in the First 1000 Days After Conception and Long-term Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study.
Early-life sugar restriction during critical developmental windows is associated with lower adult risk of MASLD and liver complications, primarily mediated by improved metabolic profiles. Policy efforts targeting sugar intake in pregnancy and early childhood may provide durable benefits for liver and metabolic health. |
| The "A-B-C" classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab.
The Atezolizumab-Bevacizumab-Cluster (A-B-C) classification for unresectable HCC identified subgroups with histology, hepatic decompensation and patterns of progression, and prognostic trajectories, informing hypothesis generation for trial design and patient selection. |
| The DILI-Inpt prognostic score to Identify hospitalized Idiosyncratic DILI patients at risk for Adverse outcomes.
The new DILI-Inpt prognostic score identified patients with the lowest likelihood of spontaneous survival. This simple prognostic score may be a useful guide for medical decision making in hospitalized DILI patients if confirmed in other cohorts. |
| Gastroenterology |
| Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation.
Collectively, this study links the detection of fecal S100A9 dimers with clinical and endoscopic disease activity in IBD and identifies inflammatory actions of S100A8 and S100A9 homodimers in the intestine. Our findings pave the way for novel diagnostic and therapeutic approaches in patients with inflammatory diseases of the intestine. |
| Gastric Organoid-Based Ectopic and Orthotopic In Vivo CRISPR Screening for Tumor Suppressors in Gastric Cancer.
In summary, we describe here a versatile model of gastric carcinogenesis that uncouples the genetics of the tumor and the host, and that faithfully recapitulates key risk factors of the malignancy. |
| Gastrointest Endosc |
| Changes to Management Influenced by Next-Generation Sequencing of Pancreatic Duct Aspirates among Patients with Main Pancreatic Duct Dilation of Unclear Etiology: A Multi-Center Cohort Study.
In a multicenter cohort of patients with MPD dilation, NGS of MPD aspirates was safe and changed surgical management for over one quarter of patients. Providers should consider MPD sampling with NGS as an ancillary diagnostic modality for patients presenting with MPD dilation of unclear etiology. |
| Disclosing a Pancreatic Cancer Diagnosis in an Era of Immediate Electronic Result Release: A National Survey of Endosonographers.
Endosonographers face communication and training challenges when delivering PDAC diagnoses. Strategies are needed to support endosonographers and minimize the negative impact of immediate test result release. |
| Durability of Cryoballoon Ablation for Eradication of Neoplastic Barrett's Esophagus: A Multicenter Prospective Cohort Study.
In patients with neoplastic BE who achieved CE-IM, CBA eradication of al dysplasia and intestinal metaplasia was safe, highly effective, and durable for at least 3 years. |
| Referral Patterns and Outcomes in Barrett's Esophagus Patients at an Expert Endoscopic Therapy Center: Impact of Radiofrequency Ablation Prior to Referral.
The proportion of patients referred after unsuccessful EET to our center is steadily increasing. With comprehensive multidisciplinary assessment and management, most patients achieve CRIM. |
| Safety of Endoscopy Following Recent Bevacizumab Use in Metastatic Colorectal Cancer.
Recent bevacizumab exposure was not associated with increased 30-day post-endoscopy perforation risk compared to other active chemotherapy, but was associated with higher bleeding risk, primarily in therapeutic (specifically EGD) procedures. |
| Gut |
| Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.
This study provides proof-of-concept supporting a nanoparticle-based agent as a LD homeostasis-targeted therapeutic to treat MASLD and related metabolic diseases. |
| Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study.
No increased risk of CRC, advanced-stage CRC or AA was observed up to 24 months. Our findings suggest that ensuring colonoscopy compliance after a positive FIT may take precedence over rigid adherence to interval. The higher the f-Hb, the sooner the colonoscopy should be performed. |
| FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis.
FOXM1 plays a pivotal role in epithelial disruption in EoE by driving proliferation and impairing differentiation. Targeting FOXM1 restores epithelial homeostasis, mitigates inflammation and offers a novel therapeutic approach for EoE. |
| Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis.
Our data indicate that the admission microbiome of patients with AP correlates with postdischarge complications independent from multiple risk factors such as AP severity, smoking or alcohol. Microbiota at admission show excellent capacity to predict postdischarge DM and may thus open new stratification tools for a tailored risk assessment in the future. |
| Hepatology |
| Differential associations of cardiometabolic risk factors with liver-related events by alcohol consumption category: Results from a large population-based study.
Excessive alcohol use appears to be the strongest factor associated with LREs. Associations between CMRFs and LREs seem similar among individuals with low and intermediate alcohol intake. Reducing alcohol intake, alongside targeted management of CMRFs, may improve strategies for preventing severe liver disease. |
| HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner.
HBV infection induces pyruvate production and decreases PPARα expression, leading to increased ROS generation and liver fibrosis. Pyruvate and PPARα represent novel targets for antifibrotic therapeutic development in CHB. |
| J Hepatol |
| A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
An 8-week glecaprevir/pibrentasvir regimen was efficacious and well-tolerated in patients with acute HCV. These results support glecaprevir/pibrentasvir use in HCV test-and-treat models, potentially streamlining the care cascade, reducing transmission, and supporting HCV elimination. Impact and implications Currently, approved hepatitis C treatments are available only for chronic HCV in most geographies, with glecaprevir/pibrentasvir recently approved in the US for acute HCV. The lack of therapeutic options delays treatment initiation, increasing the risk of disengagement among people who inject drugs and other vulnerable groups, and contributing to onward transmission. This study demonstrates that 8-week glecaprevir/pibrentasvir therapy is efficacious and safe in patients with acute HCV infection, supporting its role as a recently approved treatment for acute HCV. Availability of an approved treatment for acute HCV will support the implementation of test-and-treat strategies in outreach settings for key prevalent populations, reducing delays and improving care retention, particularly among high-risk individuals. Clinical trial number NCT04903626. |
| Geographic disparities in hepatitis B vaccine coverage across Africa: Implications for targeted interventions and 2030 goals.
Incremental gains in HepB3 uptake and widening subnational inequities threaten HBV elimination across administrative levels in Africa. High resolution coverage and dropout maps can guide precision immunization strategies to close persistent gaps and accelerate progress toward 2030 targets. Impact and implications This is the first continent-wide, fine-scale atlas of HepB vaccination in Africa. We offer governments and partners an actionable blueprint to target resources, monitor equity and accelerate progress toward the 2030 HepB3 goal-advancing precision public health for HBV control. |
| Intratumour Ploidy Heterogeneity and Clonal Evolution in Hepatocellular Carcinoma.
Our findings underscore the prognostic value of nuclear ploidy profiling in HCC and suggest that hyperploid HCCs evolve clonally from intratumour hyperploid foci and could be one of the mechanisms driving genomic instability in liver tumorigenesis. Impact and implications Modification of ploidy play a substantial role in cancer genome evolution. In this study, we created a new digital pathology method to accurately measure the hepatocyte ploidy profile of HCC. This powerful tool reveals three distinct tumor types Diploid (DP), Hyperploid (HP), and mixed Diploid/Hyperploid (DP/HP) HCCs. By clearly defining these groups, we gain crucial, new insights into the "branching" evolution of HCC tumors. This study should pave the way for novel diagnostic and therapeutic strategies. |
| MARCO<sup>+</sup> macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis.
This study uncovers a distinct immunoregulatory network in CASH, providing potential avenues for mitigating chemotherapy side effects and developing novel immunotherapeutic strategies for patients with liver metastases. |
| Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.
Sitravatinib/tislelizumab combination as second-line treatment in patients with advanced BTC demonstrated meaningful efficacy and an acceptable safety profile. Patient selection using HRD biomarkers may be a promising strategy in this setting. Impact and implications The results of this multi-center, open-label, phase 2 study suggest that immunotherapy and anti-angiogenic agent combination treatment has a promising efficacy and safety as second-line treatment for patients with advanced biliary tract cancer. Furthermore, the presence of HRD detected on tumor NGS may select patients who have benefit from this combination, which supports further research exploring immunotherapy with anti-angiogenics combination strategy in this setting. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: An Important Step Towards Mastering Metabolic Dysfunction-Associated Steatohepatitis-Targeted Therapy in Diabetes. |
| Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. |
| Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer. |
| Editorial: Remission Ambition-How Far Should We Push in Older Adults? |
| Editorial: Shingles Risk in IBD-More Evidence to Support Routine Preventive Vaccination? |
| Editorial: The Appendix-A Dead End for Treating Ulcerative Colitis, After All? |
| Review article: Seeing Is Believing-The Eosinophilic Oesophagitis Endoscopic Reference Score Can Serve as a Valuable Clinical Trial Endpoint in Eosinophilic Oesophagitis.
PEC has a role in histologic response assessment and should not be completely discounted. Evidence demonstrates that EREFS accurately reflects EoE disease activity and global oesophageal severity, and is ready to be used as a co-primary biologic endpoint in clinical trials. |
| Clin Gastroenterol Hepatol |
| A Comprehensive Narrative Review of Potential Gastrointestinal Adverse Effects from Micro(nano) Plastic Exposure.
These processes are driven by MNPs induced inflammation, immune dysregulation, and carcinogenesis. This review covers the existing evidence regarding MNPs exposure and GI harm, while also highlighting the need for further research, increased public awareness, and developed of public health strategies to mitigate plastic exposures and health impacts. |
| Blue Notes. |
| Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases.
In particular, novel anti-obesity agents such as glucagon-like peptide-1 receptor agonists offer promising potential for sustained weight loss and disease modification. This narrative review explores the impact of obesity on non-neoplastic gastrointestinal and liver diseases, the potential of intentional weight loss to mitigate its effects, and the efficacy of novel pharmacological therapies in managing obesity-related conditions. |
| Gastroenterology |
| Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases.
The present review discusses recent advances in the epidemiology, natural history, and risk factors of EoE and non-EoE EGIDs. The review also presents an update of treatment strategies according to the latest clinical guidelines and provides an overview of knowledge gaps to inform future research directions. |
| In Memoriam: Jaume Bosch, MD, PhD. |
| Gut |
| Towards optimising and standardising donor screening for faecal microbiota transplantion.
We further emphasised the importance of maintaining transparency with regard to donor recruitment, screening, monitoring and traceback record keeping. Finally, we explored future directions in donor screening, including approaches to monitoring emerging pathogens and the potential for integration of new technologies, such as metagenomic assays, to enhance and refine donor selection. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Gastric phytobezoar management using Holmium laser and a guidewire loop. |
| Clin Gastroenterol Hepatol |
| Establishing an Endobariatric Practice: Steps, Challenges, and Considerations Within a Private Practice Model. |
| Endoscopy |
| "There is a time for everything". |
| Antegrade enteral stenting for afferent loop syndrome using the double-guidewire technique via endoscopic ultrasound-guided hepaticogastrostomy. |
| Approach to closure of large mucosal wound after endoscopic resection of duodenal descending lesion: combining endoscopic hand-suturing techniques with metal clip application. |
| Ascites with suspected pneumoperitoneum: a diagnostic conundrum after negative laparotomy. |
| Challenging retrieval of a large gastric adenocarcinoma after endoscopic submucosal dissection. |
| Cold-endoscopic submucosal dissection: time to go further? |
| Dynamic functional evaluation of the anti-reflux mechanism with simultaneous endoscopy and manometry as a provocative test. |
| Endoscopic closure of a refractory gastric fistula using a novel cap-assisted poly-glycolic acid sheet application method. |
| Endoscopic immediate hemostasis strategy for palatal hematoma induced by linear endoscopic ultrasound. |
| Endoscopy E-Videos - recently published. |
| First application of carbon dioxide digital subtraction enterography for stricture evaluation in Crohn's disease. |
| Hematemesis after peroral endoscopic myotomy: always computed tomography-scan? |
| Hidden value of colon capsule endoscopy: balancing patient preference, environmental impact, and cost-effectiveness. |
| Low-cost vacuum therapy as a treatment for post-operative esophago-pleural fistula after upper pole gastrectomy. |
| Morphological features and not the timing determines the outcome of endoscopic ultrasound-guided transmural drainage of walled-off necrosis. |
| Newly developed short-length exposed-tip intraductal radiofrequency ablation probe for intra-ampullary adenocarcinoma of the ampulla of Vater. |
| Over-the-scope clip closure for afferent limb perforation during balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography in Roux-en-Y anatomy. |
| Pre-emptive purse-string suture for full-thickness resection of a gastrointestinal stromal tumor in the duodenal bulb: a case report. |
| Single versus multiple main or side-branch pancreatic duct cannulations: impact on post-ERCP pancreatitis. |
| The adaptive traction doughnut resection technique for pyloric cancer: a case of curative resection and stenosis management. |
| Traumatic pancreatic injury successfully bridged through a giant pancreatic pseudocyst. |
| Underwater closure of a sigmoid perforation with through-the-scope twin clip. |
| Gastroenterology |
| CD19 CAR T-Cell therapy for refractory ulcerative colitis. |
| Disturbance of Consciousness After Double-balloon Enteroscopy in a Patient with Peutz-Jeghers Syndrome. |
| Integrated IBD Care in the Community: Evaluating Sustainable Models and Building a Framework for the Future. |
| Hepatology |
| Letter to the Editor: Clarifying the relative contributions of collagen architecture and stiffness to antitumor immunity in GIONF-Enhanced PD-1 blockade for cholangiocarcinoma. |
| Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving functional cure. |
| J Hepatol |
| Oncolytic virotherapy to reverse therapeutic resistance in advanced liver cancer. |
| The identification of interleukin-27 as one key player in restoring virus-specific T-cell dysfunction in chronic hepatitis B virus infection. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. Authors' Reply. |
| Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer-Authors' Reply. |
| Editorial: Remission Ambition-How Far Should We Push in Older Adults? Authors' Reply. |
| Letter on 'Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis'. |
| Letter on 'Clinical Trial: Effect of a 28-Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis (EndoFOD)-A Randomised, Controlled Crossover Feeding Study'. |
| Letter on 'Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis'. |
| Letter: Affirming Cardiac Safety While Highlighting Areas for Further Research. |
| Letter: Reinterpreting the Role of Microbiota-Driven Nitric Oxide in Cirrhotic Portal Hypertension-A Maladaptive Compensatory Response? |
| Letter: Safety and Methodological Considerations for Hepatitis B Immunoglobulin Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients. |
| Gastroenterology |
| A Response to "Heavy Metals and Inflammatory Bowel Disease" Using Linked Sources of Real-World Data. |
| Clock-Constrained Evacuation and Model Over-Reach: Comment on Lamichhane et al. |
| Concerns Regarding Endoscopic Band Ligation for Dieulafoy Lesions. |
| Global MASLD Consensus: Inclusive in Scope, Exclusive in Therapy? |
| High Prevalence and Local Dissemination of Daptomycin-Resistance Mutations for Enterococcus faecium in Cirrhotic Patients. |
| Re-evaluating lifestyle interventions in normal weight metabolic dysfunction-associated steatotic liver disease. |
| Gastrointest Endosc |
| Endoscopic submucosal dissection for anal canal lesions: promising yet preliminary-a call for consensus. |
| J Hepatol |
| Further highlighting the importance of hypertension in MASLD. |